NOS1 and diabetes mellitus: In diabetic ED rats, LI-ESWT seems to downregulate the receptor of advanced glycation end products (RAGE) and upregulate factors such VEGF, nNOS, and α-SMA, leading to increased content of smooth muscles, endothelial cells, and ECM [27].